|
Interagency Coordinating Committee on Human Growth Hormone and Creutzfeldt - Jakob disease
|
Committee, Work group, Advisory group, or Task Force
|
CDC, FDA
|
NIDDK, NICHD, NINDS
|
The Public Health Service Interagency Coordinating Committee on Human Growth Hormone (hGH) and Creutzfeldt-Jakob Disease (CJD) was established in 1985 by the Assistant Secretary for Health, the Department of Health and Human Services (HHS) to review information relevant to patients who received pituitary-derived hGH that was distributed through the NIH-funded National Hormone and Pituitary Program (NHPP). The Committee analyzes this information to determine the extent of the problem of transmission of CJD (a rare, incurable brain disease) through contaminated pituitary hGH, and to inform physicians and patients who received pituitary hGH about the health risks associated with pituitary hGH. Although NHPP’s distribution of hGH ceased when its potential to transmit CJD was discovered in 1985—and today, recombinant growth hormone that is not susceptible to CJD contamination is exclusively used for treatment—the Committee continues to maintain oversight of this issue because CJD may take years or decades to develop. The Committee includes representatives from the National Institutes of Health (NIH), the Food and Drug Administration (FDA), and the Centers for Disease Control and Prevention (CDC), and is chaired by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Director.
|
|
Interagency Coordinating Committee on the Prevention of Underage Drinking (ICCPUD)
|
Committee, Work group, Advisory group, or Task Force
|
ACF, CDC, IHS, OS, OSG, SAMHSA
|
NIDA, NIAAA
|
The Consolidated Appropriations Act of 2004 directed the Secretary of Health and Human Services (HHS) to establish the Interagency Coordinating Committee on the Prevention of Underage Drinking (ICCPUD) and to issue an annual report summarizing all Federal agency activities related to preventing underage alcohol use. HHS made ICCPUD a standing committee to provide ongoing, high-level leadership on this issue and to serve as a mechanism for coordinating Federal efforts aimed at preventing and reducing underage drinking. The Substance Abuse and Mental Health Services Administration (SAMHSA) serves as the lead ICCPUD agency.
|
|
Interagency Coordinating Committee on the Validation of Alternative Toxicological Methods (ICCVAM)
|
Committee, Work group, Advisory group, or Task Force
|
ATSDR, FDA, CDC
|
NIEHS, NCI, NLM, OD
|
Interagency committee of the federal government with representatives from 17 research and regulatory agencies that require, use, generate, or disseminate toxicological and safety testing information.
|
|
Interagency Elder Justice Working Group (EJWG)
|
Committee, Work group, Advisory group, or Task Force
|
ACL
|
NIA
|
The Elder Justice Interagency Working Group brings together federal officials responsible for carrying out elder justice activities, including elder abuse prevention, research, grant and program funding, and prosecution. Since 2001, members have met informally and on a regular basis to discuss emerging issues, promising practices, and ways to coordinate their efforts. Guest speakers have addressed a range of topics, including adult protective services, guardianship, and predatory lending.
|
|
Interagency Group for Development of Lung Infection Models for P. aeruginosa and A.baumannii
|
Committee, Work group, Advisory group, or Task Force
|
BARDA, CDC, FDA
|
NIAID
|
This interagency working group meets quarterly to discuss the development of various lung infection animal models.
|
|
Interagency Group on Alzheimer's Disease and Related Dementias for implementation of the National Alzheimer's Project Act
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, CMS, FDA, HRSA
|
NIA
|
This interagency group was established by Department of Health and Human Services (HHS) in response to the Congressional directive to address Alzheimer disease. Under the National Alzheimer’s Project Act, HHS created three sub-groups on Research, Long Term Services, and Clinical Services. The Veteran’s Administration, National Science Foundation, and Department of Defense are also involved in this effort.
|
|
Interagency Modeling and Analysis Group (IMAG)
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, FDA
|
NIBIB, CSR, NCCIH, NCI, NEI, NHGRI, NHLBI, NIA, NIAAA, NIAID, NIAMS, NICHD, NIDA, NIDCD, NIDCR, NIDDK, NIEHS, NIGMS, NIMH, NIMHD, NINDS, NLM, OD/DPCPSI, OD/DPCPSI/OBSSR
|
: IMAG is comprised of program directors from over 10 government agencies including the National Institutes of Health (NIH), the National Science Foundation (NSF), Department of Energy (DOE), Department of Defense (DOD), the Department of Agriculture (USDA), the National Aeronautics and Space Administration (NASA), the Department of Veterans Administration (VA), the Food and Drug Administration (FDA), and the Intelligence Advanced Research Projects Activity (IARPA). The purpose of IMAG is to bring together program officers who have a shared interest in supporting modeling and analysis methods in biomedical, biological, and behavioral systems. IMAG has promoted and supported a wide variety of modeling, notably multi-scale modeling (MSM) through agency-specific funding opportunity announcements. IMAG also holds consortium meetings annually. The IMAG/MSM hosted a special meeting, Integrating Machine Learning with Multisscale Modeling (ML-MSM) on October 24-25, 2019. The annual MSM Consortium meeting, IMAG-AND Futures, was held virtually on March 17, 2020, that featured Multiscale Modeling Trainees that presented their MSM research in poster and podium presentations. The following two reports were published as a result of the 2019 ML-MSM Meeting, https://www.imagwiki.nibib.nih.gov/resources/meeting-reports/publicatio….
|
|
Interagency Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Working Group
|
Committee, Work group, Advisory group, or Task Force
|
CDC
|
NINDS, NIAID
|
The Interagency ME/CFS Working Group consists of multiple government agencies and patient ME/CFS patient advocacy organizations interested in research and care issues related to ME/CFS. The working group was established to help coordinate ME/CFS-related efforts across the federal agencies to enhance research efforts, improve treatment options and patient outcomes, promote public outreach, and strengthen workforce development. The working group, which is co-led by NINDS and CDC, met for the first time in August 2020, and will continue to meet regularly to provide updates, discuss issues relevant to ME/CFS research, and identify and foster communication and collaboration across the federal agencies and with ME/CFS stakeholders.
|
|
Interagency Pain Research Coordinating Committee (IPRCC)
|
Committee, Work group, Advisory group, or Task Force
|
AHRQ, CDC, FDA
|
NINDS, NCCIH, NIDA, NIDCR, NINR
|
The Interagency Pain Research Coordinating Committee is an Affordable Care Act-mandated committee to coordinate pain research activities across the government.
|
|
Interagency Select Agent Review Group (ISARG)
|
Committee, Work group, Advisory group, or Task Force
|
CDC, OS
|
NIAID, OD/OM/OB, OD/OSP
|
The Interagency Select Agent Review Group (ISARG), composed of members from the Centers for Disease Control and Prevention (CDC), the Department of Justice, the Department of State, the National Institutes of Health Office of the Director (NIH-OD) and the Biomedical Advanced Research and Development Authority (BARDA), advises the National Institute of Allergy and Infectious Diseases (NIAID) on whether facilities and procedures at NIAID-funded foreign research sites are comparable to those required by the Select Agent Regulations for domestic institutions before Select Agent work at the foreign site may proceed.
|